Shanghai Lockdown Puts New Spotlight On China COVID Policies
Calls For 'COVID Zero' Changes
The largest-ever COVID-related lockdown in Shanghai is offering an indication of the effectiveness of current Chinese policies around current controls and domestic vaccines, as well as prompting consideration of future directions for control and treatment measures as the pandemic moves to the endemic phase.
You may also be interested in...
Latest announcement from Shanghai government set to open foreign mRNA jabs to the arms of Chinese people, after months of stalling approvals.
China is signalling its intention to gradually re-open its borders amid real-world data showing few mild-to-moderate cases progress to severe symptoms. Meanwhile, Pfizer's Paxlovid is seemingly struggling to gain traction amid use guideline changes.
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.